Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747303 · ClinicalTrials.gov registry record · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
A Phase 2 study of Brain Metastases, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
- 1
- Study location
NCT02747303 is a Phase 2 study of Brain Metastases that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 166 participants, below the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target (21% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02747303, a Phase 2 study of Brain Metastases, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.
Conditions Studied
Interventions
- PROCEDURE Stereotactic Radiosurgery
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2028-08-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02747303
The ClinicalTrials.gov registry entry for NCT02747303 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 67 other Brain Metastases trials with a reported enrollment target (21% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic Radiosurgery is the first listed.
NCT02747303 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02747303 about?
NCT02747303 is a clinical study titled "Frameless Stereotactic Radiosurgery for Intact Brain Metastases". This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.
What is the current status of trial NCT02747303?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2023-09-05. Estimated completion is 2028-08-22.
What conditions does trial NCT02747303 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT02747303?
The interventions under investigation include: Stereotactic Radiosurgery (PROCEDURE).
Who is sponsoring clinical trial NCT02747303?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02747303 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active
RECRUITING · Phase 2
-
Feasibility of 18F-Fluciclovine PET/CT to Identify Brain Metastasis
RECRUITING · Phase 2
-
Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique
RECRUITING · Phase 2
-
Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance
RECRUITING · Phase 2
-
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
RECRUITING · Phase 2
-
A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.